Suriclone has a very similar pharmacological profile to the
benzodiazepine family of drugs including sedative and anxiolytic properties but with less
amnestic effects,[1][2] and its
chemical structure is quite different from that of the benzodiazepine drugs.
The mechanism of action by which suriclone produces its sedative and anxiolytic effects is by modulating
GABAA receptors, although suriclone is more subtype-selective than most benzodiazepines.[3]
References
^Gilburt SJ, Fairweather DB, Kerr JS, Hindmarch I (1992). "The effects of acute and repeated doses of suriclone on subjective sleep, psychomotor performance and cognitive function in young and elderly volunteers". Fundamental & Clinical Pharmacology. 6 (6): 251–8.
doi:
10.1111/j.1472-8206.1992.tb00118.x.
PMID1362556.
S2CID23320665.
^Blanchard JC, Julou L (March 1983). "Suriclone: a new cyclopyrrolone derivative recognizing receptors labeled by benzodiazepines in rat hippocampus and cerebellum". Journal of Neurochemistry. 40 (3): 601–7.
doi:
10.1111/j.1471-4159.1983.tb08023.x.
PMID6298365.
S2CID35732735.